CD274 and non-small cell lung carcinoma: Gastrointestinal toxicity is the most common adverse event in NSCLC receiving anti-PD-1/PD-L1 antibodies, followed by pulmonary, neurological, cutaneous, endocrine and musculoskeletal toxicities (Table 1).